Mayans, Aztecs, and indigenous Americans cultivated tobacco for medicinal and religious purposes well over 2,000 years ago. The subsequent trade and industrial-scale production of tobacco have led to its global recreational use with devastating health consequences. It is currently responsible for the greatest number of preventable deaths worldwide by any single agent, estimated to be 5 million per year by the Center for Disease Control and Prevention. The active ingredient of tobacco, nicotine, efficiently permeates the blood brain barrier and activates neuronal nicotinic acetylcholine receptors (nAChRs) in the brain. In addition, nicotine exposure of the brain during childhood and adolescence is likely to increase susceptibility to neuropsychiatric and addiction disorders.

A multitude of distinct nAChR subtypes is formed by the assembly of α1--α7, α9, and β1--β4 subunits in mammals. These nAChR subtypes are expressed in different populations of neurons and other types of cells. The nAChRs most relevant to the study of nicotine addiction are expressed in dopaminergic, glutamatergic, and GABAergic neurons, where they modulate the probability of neurotransmitter release at presynaptic terminals ([@bib17]). Studies in rodents show that nicotine use affects various behaviors ([@bib12]), including (a) impulse control and attention by modulating prefrontal cortex functions, (b) reward salience by modulating the ventral tegmental area (VTA)-striatum functions, and (c) aversive salience by modulating the medial habenula-interpenducular nucleus functions.

Multiple nAChR subtypes mediate nicotine's actions in the brain at the nanomolar concentrations found in smokers' serum. The α4β2 nAChRs in VTA projections to the nucleus accumbens ([@bib10]; [@bib15]), the α6α4β2β3 and α6β2β3 in substantia nigra pars compacta projections to the striatum ([@bib11]), and the α3α5β4 and/or α4α5β2 in medial habenula projections to the interpeduncular nucleus ([@bib2]) collectively mediate nicotine's complex behavioral effects. These nAChRs exhibit different channel kinetics, rates of desensitization, and affinities for the endogenous neurotransmitter, acetylcholine, and nicotine.

Nicotine exposure, unlike exposure to most other drugs of abuse, results in the "up-regulation" of its cognate nAChRs mediated by an increase in their abundance at the cell surface membrane in human, rodent, and primate brains ([@bib14]; [@bib1]; [@bib8]; [@bib7]; [@bib9]). Both the α4β2 nAChRs ([@bib5]; [@bib13]; [@bib6]) and the α6\* nAChRs ([@bib16]; [@bib4]) are up-regulated when nAChR-expressing cells are exposed to nanomolar nicotine concentrations as found in smokers' brains. In rodent brains, up-regulation appears to be a posttranscriptional effect: mRNA for neither the α4 nor the β2 nAChR subunits change after chronic nicotine exposure. The mechanism(s) by which nicotine up-regulates the α4β2 nAChRs, in particular, has attracted substantial attention because of the profound effect nAChR up-regulation has on the functional circuitry in which these nAChRs are expressed.

Based on experiments primarily done in vitro, which to a large degree mimic the up-regulation observed in vivo, many different mechanisms for up-regulation have been proposed ([@bib3]). These include (a) decreased nAChR turnover at the plasma membrane, (b) increased nAChR affinity for nicotine itself caused by an induced conformational change in the receptor, (c) increased trafficking of nAChR to the plasma membrane, and (d) chemical chaperoning by nicotine to catalyze subunit assembly in the ER. Among the various mechanisms proposed, a preponderance of evidence supports the intracellular chemical chaperoning effects of nicotine.

In this issue, Henderson et al. showed that nicotine up-regulates α6\* nAChRs in dopaminergic, medial habenula, and superior colliculus neurons of a knock-in mouse expressing a GFP-labeled α6 nAChR subunit. They then used normalized Förster resonance energy transfer (FRET) between the fluorescent labeled α6\* nAChR subunit and intracellular transport vesicle and organelle proteins to study mechanistic aspects of nicotine-dependent up-regulation of recombinant α6β2β3 nAChRs expressed in vitro in Neuro-2a cells. By following FRET signals between the α6 nAChR subunit and proteins at the ER exit site, in coat protein complex I (COPI)- and COPII-coated vesicles, and the cis-Golgi, they found something quite unexpected about the ability of nicotine to up-regulate α6β2β3 nAChRs. Blocking the retrograde transport of proteins from the cis-Golgi by COPI-coated vesicles completely blocked the nicotine-dependent up-regulation of α6β2β3 nAChRs at the plasma membrane. They demonstrated this by using a low concentration of the COPI inhibitor, CI-976, which selectively inhibits retrograde but not anterograde transport. They augmented this finding by showing that a mutant α6β2β3 nAChR, in which a canonical COPI-binding site motif, KKK, within the long intracellular loop of the β3 subunit is mutated to AAA, did not up-regulate in response to nicotine but rather showed normal basal expression at the plasma membrane. They also demonstrated that CI-976 blocked the up-regulation of the α4β2 nAChR in response to nicotine exposure. Thus, the retrieval of nAChRs from the cis-Golgi by COPI for effecting nicotine-dependent up-regulation is not idiosyncratic to the α6β2β3 nAChRs but instead represents a ubiquitous process by which nicotine up-regulates high sensitivity nAChRs.

The findings of [@bib4] suggest that in the presence of nicotine, rapid assembly of α4β2 nAChRs and α6β2β3 nAChRs occurs in the ER, resulting in incomplete posttranslational processing of receptors that overwhelms the ER quality control machinery. These immature nAChRs, however, are quarantined by the quality control machinery of the cis-Golgi and policed by a COPI-mediated mechanism back to the ER for proper posttranslational reprocessing. In short, the chemical chaperoning mediated by nicotine requires retrograde trafficking between the Golgi and ER to effect up-regulation of high sensitivity nAChRs at the plasma membrane of cells.

The latest Nobel Prize for Physiology or Medicine was awarded to a trio of scientists---James Rothman, Randy Schekman, and Thomas Sudhof---for their significant contributions to the understanding of the cellular mechanisms for vesicle transport, protein machinery for vesicle fusion, and signals that regulate vesicles to release their cargo with precision at synapses. The timely study by [@bib4] builds on these findings to elucidate how nicotine hijacks the cellular machinery of the ER and cis-Golgi to up-regulate nAChRs at the plasma membrane and thus nonphysiologically alter the dynamics of vesicle release at synapses to drive nicotine addiction. Finding ways to therapeutically intervene at the level of COPI--nAChR interactions, as suggested by the authors, represents a rather novel strategy to prevent nAChR up-regulation, nicotine addiction, and the deadly consequences of tobacco use on human health.
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